DAVID BOT: Open Payments
NPI 1578789335 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,378 in 87 payments from 13 companies in 2025. Trend: 2023 $1,004 · 2024 $826 · 2025 $1,378
Food & beverage: $1,267Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $229 |
| Janssen Pharmaceuticals, Inc | 8 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $193 |
| Neurocrine BioSciences, Inc. | 12 | $168 |
| ABBVIE INC. | 21 | $149 |
| Lundbeck LLC | 7 | $102 |
| Alkermes, Inc. | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
Products named: INVEGA SUSTENNA, CAPLYTA, INGREZZA, REXULTI, VRAYLAR, AUSTEDO XR, LYBALVI, COBENFY.
Industry payments across WA — which companies pay providers there.
